Related Experiment Video
Updated: Jul 8, 2025
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
Published on: March 22, 2011
Intratumoral delivery of a Tim-3 antibody-encoding oncolytic adenovirus engages an effective antitumor immune
Li Qiang1,2, Zhang Huili1, Zhang Leilei1
1College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, 310018, China.
Background And Purpose:
The use of oncolytic viruses as a gene therapy vector is an area of active biomedical research, particularly in the context of cancer treatment. However, the actual therapeutic success of this approach to tumor elimination remains limited. As such, the present study was developed with the goal of simultaneously enhancing the antitumor efficacy of oncolytic viruses and the local immune response by combining the Ad-GD55 oncolytic adenovirus and an antibody specific for the TIM-3 immune checkpoint molecule (α-TIM-3).
Approach And Key Results:
The results of Virus and cell-mediated cytotoxicity assay, qPCR, and Western immunoblotting showed that Ad-GD55-α-Tim-3 oncolytic adenovirus is capable of inducing α-TIM-3 expression within hepatoma cells upon infection, and Ad-GD55-α-TIM-3 exhibited inhibitory efficacy superior to that of Ad-GD55 when used to treat these tumor cells together with the induction of enhanced intracellular immunity. In vivo experiments revealed that Ad-GD55-α-TIM-3 administration was sufficient to inhibit tumor growth and engage in a more robust local immune response within the simulated tumor immune microenvironment.
Conclusion And Implications:
These results highlighted the promising therapeutic effects of Ad-GD55-α-TIM-3 oncolytic adenovirus against HCC in vitro and in vivo. As such, this Ad-GD55-α-TIM-3 oncolytic adenovirus may represent a viable approach to the treatment of hepatocellular carcinoma.
Insights
This study combined an oncolytic adenovirus with an antibody targeting TIM-3 to enhance cancer treatment. The novel Ad-GD55-α-TIM-3 demonstrated superior antitumor effects and boosted local immunity against hepatocellular carcinoma.
Area of Science:
- Oncolytic virotherapy
- Cancer immunotherapy
- Gene therapy
Background:
- Oncolytic viruses show promise for cancer treatment but have limited therapeutic success.
- Enhancing antitumor efficacy and local immune response is crucial for effective oncolytic virotherapy.
- Combining oncolytic adenoviruses with immune checkpoint inhibitors offers a potential strategy.
Purpose of the Study:
- To enhance the antitumor efficacy of oncolytic viruses.
- To boost the local immune response in the tumor microenvironment.
- To investigate the combined effect of Ad-GD55 oncolytic adenovirus and an antibody against TIM-3 (α-TIM-3).
Main Methods:
- In vitro studies using hepatoma cells.
- Virus and cell-mediated cytotoxicity assays.
- Quantitative PCR (qPCR) and Western immunoblotting.
- In vivo tumor growth inhibition models.
Main Results:
- Ad-GD55-α-TIM-3 induced α-TIM-3 expression in infected hepatoma cells.
- The combined Ad-GD55-α-TIM-3 showed superior inhibitory efficacy compared to Ad-GD55 alone.
- In vivo administration inhibited tumor growth and promoted a robust local immune response.
Conclusions:
- Ad-GD55-α-TIM-3 demonstrated promising therapeutic effects against hepatocellular carcinoma (HCC) in vitro and in vivo.
- This combination therapy may offer a viable new treatment approach for HCC.
- Targeting TIM-3 in conjunction with oncolytic adenovirus enhances anti-tumor immunity.
